Understanding how certain molecules affect the lifespan and function of immune cells that fight cancer.
Defining post-transcriptional mechanisms that control CD8 T cell longevity, proliferation and differentiation
['FUNDING_R01'] · UNIVERSITY OF MASSACHUSETTS AMHERST · NIH-10742910
This study is looking at how a molecule called let-7 helps important immune cells, known as CD8 T cells, survive and do their job better, especially when fighting cancer and long-lasting infections, to find ways to boost their effectiveness.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MASSACHUSETTS AMHERST (nih funded) |
| Locations | 1 site (HADLEY, UNITED STATES) |
| Trial ID | NIH-10742910 on ClinicalTrials.gov |
What this research studies
This research investigates the role of let-7, a specific molecule, in regulating the survival and differentiation of CD8 T cells, which are crucial for eliminating cancerous cells. By examining how let-7 influences these immune cells, the research aims to uncover mechanisms that could enhance their longevity and effectiveness, particularly in chronic infections and cancer. The study will involve analyzing the molecular pathways affected by let-7 to improve the immune response against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic infections or cancers that may benefit from enhanced CD8 T cell responses.
Not a fit: Patients with conditions unrelated to immune response or those not experiencing chronic infections or cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies that enhance the immune system's ability to fight cancer.
How similar studies have performed: Previous research has shown promising results in manipulating immune cell functions, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
HADLEY, UNITED STATES
- UNIVERSITY OF MASSACHUSETTS AMHERST — HADLEY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: POBEZINSKIY, LEONID — UNIVERSITY OF MASSACHUSETTS AMHERST
- Study coordinator: POBEZINSKIY, LEONID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer